WuXi Biologics announces new discovery, development and manufacturing site in China

By Flora Southey contact

- Last updated on GMT

WuXi Biologics has broken ground on its Biologics Innovation Center in Shanghai, China
WuXi Biologics has broken ground on its Biologics Innovation Center in Shanghai, China

Related tags: Wuxi biologics, CDMO, China

The CDMO has broken ground on its 1.6 million-square-foot Biologics Innovation Center in Shanghai.

Contract development and manufacturing organisation (CDMO) WuXi Biologics has announced plans to build its Biologics Innovation Center in the Fengxian district of Shanghai.

The 1.6 million-square-foot centre will house discovery and development laboratories, alongside good manufacturing practice (GMP) capabilities for commercial production.

WuXi Biologics' Innovation Center, Shanghai, China

Laboratory facilities are due to open in 2019, with GMP manufacturing expected to launch in 2021. The site will accommodate more than 3,000 scientists recruited predominantly from China.

According to CEO Chris Chen, the build responds to growing demand for the manufacture of large molecule drugs: “We have a portfolio of 187 biologics [that require] manufacturing and the number of projects is still growing,” ​we were told. The Innovation Center brings “everything in one place,” ​he continued.

The firm did not disclose the cost of the build, nor provide specifics on the site’s “significant”​ bioreactor capacity.

The announcement adds to the Chinese CDMO’s growing site network, which also includes plans for international expansion in Ireland​, Singapore​, and the US​.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars